She bought 3 Abbott shares for $180 in 1935; after her death at 100, her $7 million fortune went to help college students
Grace Groner, a secretary at Abbott Laboratories, lived a modest life in Lake Forest, Illinois, despite her investment of $180 in three Abbott shares in 1935 growing to over $7 million. Upon her death at 100 in 2010, she bequeathed her entire fortune to a foundation benefiting students at Lake Forest College, her alma mater. Her generosity, though not fully known during her lifetime, now provides scholarships and service-learning opportunities for students, reflecting her lifelong connection to the institution.
Insulet (PODD) Reworks Debt Terms, Is It Still Trading At A Discount?
Insulet (PODD) recently reworked its credit agreement, converting $475 million of term loans into new debt with lower interest rates and expanding its revolving credit facility to $750 million. Despite a significant share price decline, the company's stock is still considered 23% undervalued, with a fair value of $171.91, according to an analysis based on its product roadmap and recurring revenue model. However, the narrative acknowledges risks related to type 2 user retention and potential recall-related quality issues.
Abbott Laboratories stock reports 4.8 percent Q2 sales growth
Abbott Laboratories reported 4.8% comparable sales growth in Q2 2026, with adjusted EPS reaching USD 1.31, surpassing guidance. The company raised its full-year adjusted EPS guidance and is scheduled to report Q3 2026 results on October 21, 2026. Analysts have a consensus "Moderate Buy" rating with an average 12-month target price significantly above the current trading price.
Medtronic's 49-Year Dividend Streak Faces a New Challenge: Is Growth Finally the Real Story?
Medtronic (MDT), known for its 49-year dividend streak, is experiencing a shift in its investment thesis due to remarkable growth in its cardiac ablation solutions, which grew 88% worldwide. While the dividend provides a floor for the stock, its rapid growth in medical device sectors like ablation is becoming the primary driver for investor interest. Despite its stock performance over the past five years, Medtronic is currently undervalued based on forward earnings, suggesting potential upside if this growth continues.
Abbott Laboratories (ABT) Launches SimpleScreen CRC As Fair Value Debate Heats Up
Abbott Laboratories (ABT) has launched SimpleScreen CRC, an FDA-approved and Medicare-covered blood test for colorectal cancer, targeting individuals aged 45 and older who avoid traditional screening. This launch occurs as ABT shares have seen a significant year-to-date decline, prompting a debate over the company's fair valuation, with different models suggesting the stock is either undervalued or expensive. The article explores these conflicting valuation narratives and potential risks and opportunities for investors.
How to Create a Million-Dollar Stock Portfolio
This article discusses strategies for building a million-dollar stock portfolio, drawing lessons from successful non-professional investors like Ronald Read, Anne Scheiber, and Grace Groner. These investors achieved significant wealth by investing for decades, rarely selling, and reinvesting dividends in blue-chip companies. The article highlights three specific stocks—Wells Fargo (WFC), Abbott Laboratories (ABT), and AbbVie Inc. (ABBV)—as examples of long-term investment opportunities, emphasizing their dividend yields and growth potential.
At $98.83 each, Abbott (ABT) director John G. Stratton acquires 397 share-linked units.
Abbott Laboratories director John G. Stratton acquired 397 Stock Equivalent Units on September 30, 2026, at a price of $98.83 per share. These units are credited to a director-fee account under a grantor trust and are generally paid in cash upon retirement or reaching age 65, earning the same return as if invested in Abbott shares. Following this transaction, Stratton's balance stands at 14,499 Stock Equivalent Units.
Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday
This article compiles ten top analyst forecasts for Friday, featuring various stock rating changes and price target adjustments. Notably, Rothschild & Co upgraded Abbott Laboratories (ABT) to Buy and raised its price target, suggesting a potential rally of over 31% based on its Thursday closing price. Other companies like Accenture, CSX, Nike, and Marathon Petroleum also received updated ratings and price targets from different analysts.
Here Are Friday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Cerebras Systems, Coinbase Global, Edison International, Northrop Grumman, Pershing Square, Robinhood Markets, and More
This article compiles the top Wall Street analyst upgrades, downgrades, and new initiations for Friday, October 2, 2026, featuring companies like Abbott Laboratories, Airbnb, and Northrop Grumman. It also provides a market recap, noting that stocks recovered from a volatile Thursday, oil prices surged past $100, and Treasury yields saw significant movement. The report emphasizes that individual analyst reports should not be the sole basis for investment decisions.
This Hewlett Packard Enterprise Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
This article highlights five significant analyst upgrades for Friday, October 2, 2026. Key upgrades include Hewlett Packard Enterprise (HPE) from Neutral to Outperform, Abbott Laboratories (ABT) from Neutral to Buy, Airbnb (ABNB) from Sector Weight to Overweight, Horizon Bancorp (HBNC) from Neutral to Overweight, and Triumph Financial (TFIN) from Neutral to Buy. Analysts have also raised price targets for most of these companies, reflecting a more bullish outlook.
Here Are Friday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Cerebras Systems, Coinbase Global, Edison International, Northrop Grumman, Pershing Square, Robinhood Markets, and More
This article compiles top Wall Street analyst research calls from Friday, October 2, 2026, including upgrades for companies like Abbott Laboratories and Airbnb, and downgrades for Northrop Grumman and Edison International. It also details new initiations for Coinbase Global and Robinhood Markets, alongside updates on pre-market stock futures, treasury bonds, oil, gold, and cryptocurrency market performance.
Rothschild & Co Redburn Upgrades Abbott Laboratories to Buy From Neutral, Adjusts PT to $127 From $119
Rothschild & Co Redburn has upgraded its rating for Abbott Laboratories (ABT) from Neutral to Buy, simultaneously increasing its price target to $127 from $119. The article notes that Abbott Laboratories currently holds an average overweight rating with a mean price target of $121.08. Access to the full details of this report requires a premium subscription.
Rothschild Redburn upgrades Abbott Labs stock rating on device strength
Rothschild Redburn has upgraded Abbott Laboratories (ABT) to Buy from Neutral, raising its price target to $127 from $119, citing strong growth expectations for the company's Medical Devices business, particularly in cardiovascular and diabetes technology. The firm also noted the positive impact of the Exact Sciences acquisition on Abbott's diagnostics division and its strong position to meet mid-term growth guidance. This upgrade comes after Abbott reported solid second-quarter results and raised its full-year EPS guidance.
Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript
This article provides the transcript for Abbott Laboratories' (ABT) Q2 2026 Earnings Call, which took place on July 16, 2026, at 9:00 AM EDT. It lists the company participants, including the Chairman and CEO Robert Ford, and CFO Phil Boudreau, as well as the analysts who participated from various financial institutions.
Rothschild Redburn upgrades Abbott Labs stock rating on device strength By Investing.com
Rothschild Redburn has upgraded Abbott Laboratories (NYSE:ABT) to Buy from Neutral, setting a new price target of $127, citing strong performance in its Medical Devices business, particularly cardiovascular and diabetes operations. The firm expects significant organic growth in these segments and highlights the positive impact of the Exact Sciences acquisition on diagnostics. Abbott is positioned to meet its mid-term growth guidance, with further upside potential if it addresses its conglomerate structure.
Mississippi awarded more than $771,000 in Abbott Infant Formula Settlement
Mississippi will receive over $771,000 from a multi-state settlement with Abbott Laboratories. The settlement addresses allegations that Abbott sold infant formula and nutritional products that did not meet safety standards while being paid for through government health programs. Abbott will pay more than $348 million nationwide to resolve these federal and state claims related to products manufactured between 2018 and 2022.
Digital Realty backs Abbott's Texas data center investment plan
Digital Realty (NYSE: DLR) has affirmed its commitment to responsible data center growth in Texas, supporting Governor Abbott's initiative. The company pledged to work with officials, regulators, and utilities to ensure grid reliability, consumer protection, and responsible resource management amidst increasing demand for AI and cloud services. CEO Andy Power emphasized constructive engagement to find solutions benefiting all Texans.
AMA approves permanent CPT codes for Medtronic's devices treating urinary incontinence and hypertension.
The American Medical Association (AMA) has approved new Category I CPT codes for Medtronic's Altaviva™ and Symplicity Spyral™ devices, which treat urge urinary incontinence and uncontrolled hypertension, respectively. These codes, effective January 2028, are expected to improve reimbursement and patient access to these minimally invasive therapies. Medtronic PLC shares saw a slight decline of 0.88% at the time of the report.
Abbott settled a government infant formula lawsuit for nearly $385 million.
Abbott Laboratories has agreed to pay nearly $385 million to settle a whistleblower lawsuit alleging that the company sold infant formula that failed to meet federal standards to WIC and Medicaid programs. The lawsuit claimed Abbott knowingly produced formula in unsanitary conditions at its Sturgis, Michigan plant and concealed contamination results. The settlement resolves claims related to two plants, with the bulk of the money going to the federal government and participating states, but no funds are available directly to individual consumers.
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?
This article compares Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) as investment opportunities in 2026, weighing their respective strengths, financial performance, risk profiles, and valuations. While Abbott offers diversified stability across various healthcare segments, Intuitive Surgical provides high-growth potential in the specialized field of robotic-assisted surgery. The author ultimately recommends Intuitive Surgical due to its dominant market position and recurring revenue model.
Medtronic reveals cardiac mapping and ablation software clearances
Medtronic announced it has received regulatory clearances for new cardiac mapping and ablation software in both the U.S. and Europe. The clearances are for its Affera Prism-2 Mapping Software and a CE mark for the PulseSelect ProxBox Adapter with Proximity Indicator software, aiming to enhance the company's position in the competitive pulsed field ablation market. These software advancements are designed to provide physicians with better visualization and real-time feedback during cardiac ablation procedures.
In 1935, An Illinois Secretary Bought 3 Shares Of Her Company's Stock For $180. She Never Sold A Single Share And Always Reinvested Dividends. By The Time She Died In 2010 Her 3 Abbott Shares Had Turned Into $7.2 Million.
Grace Groner, a secretary at Abbott Laboratories, purchased three shares of the company's stock for $180 in 1935. She never sold a single share and consistently reinvested all dividends. By the time she died in 2010, her initial investment had grown to $7.2 million, which she bequeathed to Lake Forest College for student scholarships.
DOJ Announces $385 Million Settlement to Resolve False Claims Allegations over Abbott Laboratories Baby Formula
The Department of Justice announced a $385 million settlement with Abbott Laboratories to resolve False Claims Act allegations related to its baby formula production. The settlement addresses claims that Abbott knowingly sold contaminated powdered infant formula from its Sturgis, MI facility, failing to meet safety standards. The alleged misconduct included ignoring roof leaks, using temporary fixes, operating with cracked spray dryers, and failing to test for or disclose bacterial contamination, putting infants at risk.
Tandem Diabetes Care (TNDM) Is Up 7.2% After International Launch Of Mobi Insulin Pump System
Tandem Diabetes Care (TNDM) stock rose 7.2% following the international launch of its Mobi insulin pump system in 12 countries, integrating with Dexcom G7 CGM and Control-IQ+ technology. This expansion supports Tandem's goal of broader international adoption and reinforces its focus on sensor interoperability and recurring supply revenue. Analysts project significant revenue and earnings growth for Tandem Diabetes Care, with a fair value indicating a potential 79% upside.
Abbott (ABT) Stock May Be 25% Stretched After Biosensor Market Forecast
Abbott Laboratories' stock price has fallen 22.9% over the past year, leading to questions about its valuation relative to its cash flows. While new growth areas like wearable biosensors offer potential, a Discounted Cash Flow (DCF) model suggests the current share price of $100.95 is still meaningfully above its estimated intrinsic value, indicating the stock may be stretched. However, some community narratives suggest the stock could be undervalued if the company successfully converts its medical technology pipeline into sustained sales growth and margin expansion.
Abbott Labs launches blood test to screen for colorectal cancer
Abbott Laboratories' Madison-based cancer diagnostics business has launched a new blood-based colorectal cancer screening test called SimpleScreen CRC. This new test aims to provide an alternative screening option for the estimated 60 million Americans who are overdue for colon screenings, especially for those who decline or do not complete traditional stool-based tests or colonoscopies. While traditional methods remain preferred by the American Cancer Society, this blood test offers a convenient option to detect colorectal cancer and precancerous growths at earlier, more treatable stages.
Abbott Laboratories stock after-hours at EUR 87.96: minus 0.85 percent versus prior close
Abbott Laboratories stock traded at EUR 87.96 after-hours on September 30, 2026, marking a 0.85 percent decrease from its prior close. The company also announced the U.S. launch of SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test. Abbott is set to release its third-quarter 2026 financial results on October 21.
Abbott Labs launches blood test to screen for colorectal cancer
Abbott Laboratories has launched a new blood-based screening test called SimpleScreen CRC for colorectal cancer, offering an alternative for individuals who are not undergoing traditional colonoscopies or stool-based tests. While not as sensitive in detecting precancerous growths as preferred methods, this test aims to increase screening rates among the 60 million Americans overdue for colon screenings. SimpleScreen CRC detects molecular signals of colorectal cancer in DNA fragments in the blood and is covered by traditional Medicare.
Mississippi receives $771K in Abbott formula settlement
Mississippi is set to receive $771,432.52 from Abbott Laboratories as part of a $385 million national settlement. This settlement addresses allegations that the company operated a manufacturing plant with unsanitary conditions, leading to contaminated powdered baby formula and a nationwide shortage in 2022. Attorney General Lynn Fitch emphasized holding Abbott accountable for betraying public trust and defrauding taxpayers, despite the company not admitting liability.
Mississippi to receive more than $771K in $384 million Abbott Laboratories settlement
Mississippi will receive over $771,000 as part of a $384 million nationwide settlement with Abbott Laboratories. The settlement addresses allegations that Abbott defrauded government health programs by selling infant formula from facilities that failed safety standards, particularly concerning microorganism contamination. Attorney General Lynn Fitch emphasized the importance of protecting families and taxpayer-funded health programs, noting that the settlement resolves allegations without constituting an admission of liability.
AG Fitch Announces False Claims Settlement with Abbott Laboratories
Mississippi Attorney General Lynn Fitch has announced a False Claims Settlement with Abbott Laboratories. The article references an unrelated past Supreme Court ruling concerning Fitch's authority to investigate cases. This settlement is a separate matter.
Abbott Laboratories (ABT) Launches SimpleScreen CRC As Fair Value Stays In Focus
Abbott Laboratories (ABT) has launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening, amidst fluctuating stock performance. While the company's one-month share price has fallen, its 90-day return is up, and a common narrative suggests the stock is 16% undervalued. However, differing valuation models and potential pressures like legal settlements and expansion spending present mixed signals for investors.
Abbott Launches Simplescreen Crc Blood Test in the U.S
Abbott has announced the U.S. commercial launch of SimpleScreen™ CRC, an FDA-approved blood test for colorectal cancer screening in average-risk adults aged 45 and older. The test, developed by Freenome, showed 81.1% overall sensitivity for colorectal cancer in clinical trials and is covered by Medicare. This new offering expands Abbott's colorectal cancer screening portfolio, aiming to provide a convenient screening option for those who might not undergo other preferred methods.
Abbott launches Freenome’s colorectal cancer screening test
Abbott is launching Freenome’s SimpleScreen CRC blood-based test for colorectal cancer in the U.S., adding it to its existing portfolio which includes the Cologuard Plus stool-based test. This new test is intended for individuals who decline medical guideline-recommended screening and demonstrated 81.1% sensitivity for colorectal cancer in an analysis. The SimpleScreen CRC test is covered by Medicare, offering no out-of-pocket costs for eligible patients.
Abbott launches Freenome’s colorectal cancer screening test
Abbott is launching Freenome's SimpleScreen CRC blood-based test for colorectal cancer in the U.S., adding to its screening portfolio. The test, which recently received FDA approval, is an option for individuals resistant to colonoscopies or stool tests, specifically for adults aged 45 and older at average risk. SimpleScreen CRC boasts 81.1% sensitivity for colorectal cancer and is covered by Medicare.
Mississippi to Receive $771K in $384M False Claims Settlement with Abbott Laboratories
Mississippi Attorney General Lynn Fitch announced a $384 million settlement with Abbott Laboratories over allegations of defrauding government health programs by selling infant formula and nutritional therapy products made in plants that failed safety standards. Mississippi will receive $771,432.52 from the settlement. The allegations state that Abbott knowingly manufactured infant formula in an environment susceptible to microorganism contamination and failed to disclose test results to the FDA.
Abbott Laboratories stock trades at EUR 88.79 after Q2 beat
Abbott Laboratories stock is trading at EUR 88.79 after reporting strong Q2 2026 results, with adjusted EPS of USD 1.31 and revenue of USD 12.59 billion, surpassing analyst expectations. The company raised its full-year 2026 adjusted EPS guidance to USD 5.45-5.60 and maintains a positive outlook, with TD Cowen reiterating a Buy rating and a USD 135.00 price target. Abbott's next earnings report is scheduled for October 20, 2026.
In 1935, Grace Groner, a secretary, invested $180 in her employer Abbott; 75 years later, it had grown to
Grace Groner, a secretary at Abbott Laboratories, invested $180 in the company's stock in 1935. She held onto these shares for 75 years, and by her death in 2010 at age 100, her estate was valued at approximately $7 million. Despite her wealth, Groner lived a modest lifestyle and bequeathed her fortune to Lake Forest College, her alma mater, to support student programs.
Abbott launches SimpleScreen CRC, a blood-based colorectal cancer screening test for adults 45+, covered by Medicare.
Abbott has launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in adults aged 45 and older. This test is covered by Medicare and aims to increase screening rates by offering a convenient alternative to traditional methods. Despite this new product, Abbott Laboratories (ABT) stock is trading near its 52-week low, with more selling pressure observed on the Pluang platform.
Abbott Laboratories stock pre-market at EUR 89.14: plus 0.48 percent
Abbott Laboratories stock showed a pre-market gain of 0.48 percent, trading at EUR 89.14 on September 30, 2026. This follows the prior close of EUR 88.71. Recent news affecting the company includes a settlement with the U.S. Justice Department regarding infant-formula allegations and the launch of a new Similac infant formula product.
Nexalin Technology Taps Neuromodulation Commercial
Nexalin Technology, developer of Deep Intracranial Frequency Stimulation (DIFS™) technology, has appointed Robert DiTota as Senior Strategic Advisor, Global Commercialization. This move signifies the company's shift from clinical development to commercializing its Gen-2 SYNC device, already approved in China, Brazil, Oman, and Israel, with plans to expand into the US and Europe. DiTota, with over two decades of experience in neuromodulation at Abbott and Medtronic, will advise on global commercial strategy and infrastructure development.
A brain-stimulation device is approved in four countries. Nexalin is building a sales network.
Nexalin Technology (NXL) has appointed Robert DiTota as Senior Strategic Advisor for global commercialization, effective September 15, 2026, to leverage existing device approvals into sales. DiTota, with extensive experience from Medtronic and Abbott, will focus on distribution, market development, and infrastructure for Nexalin's Gen-2 SYNC device, which is already approved in China, Brazil, Oman, and Israel. The company plans to expand into the U.S. and Europe as regulatory milestones are met, building on positive clinical trial results for its device.
Medtronic (NYSE:MDT) Stock Price
This page provides an overview of Medtronic (NYSE:MDT) stock, including its current price performance, analyst consensus targets, and various user-submitted fair value narratives. It highlights recent news and updates, key financial details, and information about the company's segments and competitors. The stock is currently trading at US$89.50, with a fair value estimate of US$98.00, suggesting it is undervalued.
Abbott Laboratories stock trades at EUR 88.71 versus EUR 88.77, minus 0.07 percent
Abbott Laboratories stock was trading at EUR 88.71, down 0.07 percent from its prior close of EUR 88.77 on September 29, 2026. The company reported a 13.0 percent increase in Q2 revenue to USD 12.593 billion and adjusted EPS of USD 1.31. Abbott also raised its full-year 2026 adjusted EPS guidance and saw strong growth in its Medical Devices segment.
3 Historically Stable Dividend Raisers in Medical Devices Offering Solid Yields With Fortress-Like Growth
This article highlights three medical device companies—Abbott Laboratories (ABT), Medtronic (MDT), and Becton Dickinson (BDX)—as stable dividend raisers offering solid yields for retirement portfolios. These companies benefit from consistent demand for their products, allowing them to increase dividends annually. The article details each company's dividend history, safety, and investment case, noting their strong free cash flow and modest forward earnings multiples.
Nexalin appoints Robert DiTota as senior strategic advisor
Nexalin Technology, Inc. has appointed Robert DiTota as Senior Strategic Advisor, Global Commercialization, effective September 15. DiTota will guide the company's commercial strategy, international distribution, and market development for its neurostimulation platform. This appointment signals Nexalin's transition from clinical development to commercialization of its Deep Intracranial Frequency Stimulation technology, leveraging DiTota's extensive experience from Medtronic and Abbott.
Form 4 Abbott Laboratories For: 29 September By Investing.com
This article announces the filing of a Form 4 for Abbott Laboratories on September 29. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by company insiders. The filing date is confirmed as September 29, 2026, and is accompanied by an Investing.com attribution.
Form 4 Abbott Laboratories For: 29 September By Investing.com
This article announces the filing of a Form 4 for Abbott Laboratories on September 29. It briefly mentions the company's stock symbol (ABT) and current price movement. The content is primarily a placeholder for the Form 4 details, indicating it's an insider trading report.
GE HealthCare Technologies Inc. (GEHC) Latest Stock News & Headlines
This article provides a compilation of recent news and headlines concerning GE HealthCare Technologies Inc. (GEHC). It covers various topics including dividend announcements, stock performance analysis, market trends in remote cardiac monitoring, and the appointment of new board members. The collected headlines also discuss GEHC's strategic moves like the launch of its CareIntellect AI tool and potential acquisitions.
Abbott Laboratories (ABT) stock price, news, quote and history
This page provides an overview of Abbott Laboratories (ABT) stock, including its current price, recent news headlines, dividend information, and performance metrics. As of September 29, 2026, ABT was trading at 100.95 USD, with a slight dip after hours, and had announced a cash dividend of $0.63. The news section highlights recent analyst opinions and company-specific events affecting ABT and related healthcare stocks.
